Sage Faces Multiple Moments Of Truth For Zuranolone, GABA Modulation

Parkinson’s Data For NMDA Modulator Also On Tap Before Year’s End

 
• By Mandy Jackson

Before pivotal depression data in 2021 attempt to redeem zuranolone after a failed Phase III study, the company will report Phase II results for next-gen GABA modulator SAGE-324 in essential tremor.

A man standing on top of a mountain as the sun sets
Sage may get a shot at redemption with zuranolone in depression • Source: Shutterstock

More from Neurological

More from Therapy Areas